Pharmacokinetics, Relative Bioavailability and Safety of INL-001 Compared to Marcaine After Open Hernioplasty

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-06-02

Study Completion Date

2017-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multicenter randomized, single-blind, controlled study. The primary objectives of this study are to obtain the pharmacokinetic profile and the relative bioavailability of the INL-001 matrix during and after open hernioplasty compared to Marcaine™ 0.25% infiltration.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Open-label Safety and Pharmacokinetic Study of INL-001 in Adults Following Various Open Soft-Tissue Surgeries

NCT04785638

Pain, Postoperative Hernia, Ventral Abdominoplasty +3 more

COMPLETED PHASE3

Efficacy, Safety and Pharmacokinetic Profile of a Collagen Bupivacaine Implant in Men After Open Mesh Herniorrhaphy

NCT00626886

Postoperative Pain Inguinal Hernia

COMPLETED PHASE2

Safety and Efficacy of CollaRx® Bupivacaine Implant in Men After Open Laparotomy Herniorrhaphy

NCT01220024

Herniorrhaphy Postoperative Pain Inguinal Hernia

COMPLETED PHASE2

Pharmacokinetics, Relative Bioavailability and Safety of Xaracoll Implant

NCT02232178

Hernioplasty

COMPLETED PHASE2

Efficacy and Safety Study of Postsurgical Analgesia With INL-001 in Abdominoplasty

NCT04785625

Pain, Postoperative Abdominoplasty

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter randomized, single-blind, controlled study. Prior to surgery on Day 1, 48 subjects who continue to meet study entry criteria will be randomized just prior to surgery in a 2:1 ratio to receive either 3 x 100 mg INL-001 bupivacaine HCl collagen-matrix implants (total bupivacaine HCl dose 300 mg) or Marcaine 0.25% (bupivacaine HCl) 175 mg infiltration. Subjects will then undergo open hernioplasty according to standard procedure.

Subjects will remain in the clinic at least until after the 72 hour blood sample has been collected for PK analysis on Day 4. Subjects discharged after the 72 hour blood draw will be instructed to return to the clinic to complete the 96 hour PK blood draw on Day 5. Follow-up safety assessments will include clinic visits on Day 7, Day 15 and Day 30.

Pharmacokinetic blood samples will be collected from subjects before surgery and at predetermined time points up to 96 hours after administration of study drug. Safety assessments will include frequent assessment of vital signs through 72 hours, continuous electrocardiogram (ECG) monitoring for at least 24 hours, oxygen saturation levels, and adverse events (AEs) reporting with particular emphasis on the signs and symptoms of CNS and cardiovascular bupivacaine toxicity. The surgical wound will be assessed frequently for adverse events associated with altered wound healing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hernioplasty

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Participants

This is a single-blind study in which the study subject is blinded to treatment group. All precautions will be taken to ensure that the blinding of the treatment group is maintained throughout the study period. Unblinding to the subject will not be permitted unless it is deemed necessary for appropriate treatment of a medical emergency.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

INL-001

3 x 100 mg INL-001 (bupivacaine HCl collagen implants). Total bupivacaine HCl dose 300 mg.

Group Type EXPERIMENTAL

INL-001 (bupivacaine HCl collagen implant)

Intervention Type COMBINATION_PRODUCT

3 x 100 mg INL-001 bupivacaine HCl collagen-matrix implants (total bupivacaine HCl dose 300 mg)

Marcaine 0.25% infiltration

Marcaine 0.25% infiltration (bupivacaine HCl 175 mg).

Group Type ACTIVE_COMPARATOR

Marcaine 0.25% infiltration

Intervention Type DRUG

Marcaine 0.25% (bupivacaine HCl) 175 mg infiltration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

INL-001 (bupivacaine HCl collagen implant)

3 x 100 mg INL-001 bupivacaine HCl collagen-matrix implants (total bupivacaine HCl dose 300 mg)

Intervention Type COMBINATION_PRODUCT

Marcaine 0.25% infiltration

Marcaine 0.25% (bupivacaine HCl) 175 mg infiltration

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

INL-001 Marcaine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

To be eligible for inclusion into the study, subjects must:

* Be a man or woman ≥18 years of age.
* Be eligible for unilateral inguinal hernioplasty with mesh (open laparotomy, tension-free technique) performed according to standard surgical technique under general anesthesia. Repair of multiple hernias through a single incision is permitted. If female of childbearing potential, have a negative pregnancy test at screening and before randomization on Day 1 AND be using an effective contraception method (ie, abstinence, intrauterine device \[IUD\], hormonal \[estrogen/progestin\] contraceptives, or barrier control) for at least one menstrual cycle prior to study enrollment and for the duration of the study, OR be surgically sterile, OR be a postmenopausal female (no menses for at least 1 year or hysterectomy).
* Has the ability and willingness to comply with the study procedures.
* Be willing to use only permitted medications throughout the study.
* Be willing to use opioid analgesia.
* Be able to fluently speak and understand either English or Spanish and be able to provide meaningful written informed consent for the study.

Exclusion Criteria

A subject will be excluded from study participation if prior to surgery he/she:

* Has a known hypersensitivity to amide local anesthetics, morphine, acetaminophen, or bovine products.
* Is scheduled for bilateral inguinal hernioplasty or other significant concomitant surgical procedure.
* Has undergone major surgery within 3 months of the scheduled hernioplasty or plans to undergo another laparotomy procedure within the 30 day postoperative period.
* Has known or suspected history of alcohol or drug abuse or misuse within 3 years of screening or evidence of tolerance or physical dependency on opioid analgesics or sedative-hypnotic medications.
* Has any clinically significant unstable cardiac, neurological, immunological, renal, hepatic or hematological disease or any other condition that, in the opinion of the investigator, could compromise the subject's welfare, ability to communicate with the study staff or otherwise contraindicate study participation.
* Has venous access difficulties that may preclude the frequent pharmacokinetic sampling requirements of the study.
* Has participated in a clinical trial (investigational or marketed product) within 30 days of surgery.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No